NASDAQ:ONCE - Spark Therapeutics Stock Price, Forecast & News

Spark Therapeutics trades on the NASDAQ under the ticker symbol "ONCE."

Spark Therapeutics Inc (NASDAQ:ONCE) posted its earnings results on Tuesday, August, 7th. The biotechnology company reported ($0.77) EPS for the quarter, missing the consensus estimate of ($0.43) by $0.34. The biotechnology company had revenue of $25.19 million for the quarter, compared to the consensus estimate of $29.44 million. Spark Therapeutics had a negative return on equity of 59.10% and a negative net margin of 358.41%. View Spark Therapeutics' Earnings History.

7 brokers have issued 12 month price targets for Spark Therapeutics' shares. Their forecasts range from $113.48 to $115.00. On average, they expect Spark Therapeutics' share price to reach $114.41 in the next year. This suggests a possible upside of 0.7% from the stock's current price. View Analyst Price Targets for Spark Therapeutics.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Spark Therapeutics in the last year. There are currently 7 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Spark Therapeutics.

News headlines about ONCE stock have been trending somewhat negative recently, InfoTrie reports. The research firm rates the sentiment of press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Spark Therapeutics earned a media sentiment score of -1.0 on InfoTrie's scale. They also assigned news stories about the biotechnology company a news buzz of 5.0 out of 10, indicating that recent press coverage is somewhat likely to have an effect on the company's share price in the near future. View News Stories for Spark Therapeutics.

Some companies that are related to Spark Therapeutics include NOVOZYMES A/S/S (NVZMY), Neurocrine Biosciences (NBIX), Qiagen (QGEN), BIO-TECHNE (TECH), BioNTech (BNTX), Moderna (MRNA), argenx (ARGX), Repligen (RGEN), Acceleron Pharma (XLRN), China Biologic Products (CBPO), bluebird bio (BLUE), Adaptive Biotechnologies (ADPT), Ablynx (ABLYF), Crispr Therapeutics (CRSP) and Momenta Pharmaceuticals (MNTA).

Based on aggregate information from My MarketBeat watchlists, some companies that other Spark Therapeutics investors own include Brainstorm Cell Therapeutics (BCLI), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Gilead Sciences (GILD), AbbVie (ABBV), Exelixis (EXEL), BioMarin Pharmaceutical (BMRN), Celgene (CELG) and Netflix (NFLX).

(ONCE) raised $88 million in an IPO on Friday, January 30th 2015. The company issued 5,500,000 shares at $15.00-$17.00 per share. J.P. Morgan and Credit Suisse acted as the underwriters for the IPO and Cowen and Company and Sanford C. Bernstein were co-managers.

Shares of ONCE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ONCE stock can currently be purchased for approximately $113.57.

Spark Therapeutics has a market capitalization of $4.37 billion and generates $64.72 million in revenue each year. The biotechnology company earns $-78,820,000.00 in net income (profit) each year or ($2.11) on an earnings per share basis. Spark Therapeutics employs 368 workers across the globe.View Additional Information About Spark Therapeutics.

The official website for Spark Therapeutics is http://www.sparktx.com/.

Spark Therapeutics' mailing address is 3737 MARKET STREET SUITE 1300, PHILADELPHIA PA, 19104. The biotechnology company can be reached via phone at 888-772-7560 or via email at [email protected]